Q1 2022 Results
Company overview
Financial performance
CRM
Financial review
Immunology
Neuroscience
2022 priorities
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
Abbreviations
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Cosentyx® - IL-17A inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04179175 (CAIN457M2301E1)
Hidradenitis Suppurativa (HS)
Phase 3
745
Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR)
Secukinumab 300 mg every 2 weeks
Secukinumab 300 mg every 4 weeks
Patients with moderate to severe hidradenitis suppurativa completing either of the
core trials AIN457M2301 (NCT 0313632) or AIN567M2302 (NCT03713619)
Target Patients
Read-out Milestone(s)
2025
Publication
Study design SHSA 2020
NCT04181762 SELUNE (CAIN457Q12301)
Lupus Nephritis
Phase 3
460
Proportion of subjects achieving protocol-defined CRR
Secukinumab 300 mg s.c.
Placebo s.c.
Patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co-
existing class V features)
2026
2026
60 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation